Jakavi
Novartis’ Jakavi Phase 3 trial is first of its kind to hit main goal in steroid-refractory acute graft-versus-host disease
April 23, 2020Research and Development Jakavi, Novartis, pharrma
Novartis has revealed impactful new Phase 3 data for its therapy Jakavi (ruxolitinib) in the treatment of patients with steroid-refractory …
Novartis presents strong results in rare blood disorder trials
June 10, 2016Medical Communications, Research and Development Jakavi, Novartis, Revolade, blood disorder
Novartis has released data from two late-stage trials for rare blood disorders, which showed that Javi (ruxolitinib) is superior to …
Incyte to stop Jakafi pancreatic, colorectal cancer drug trials
February 11, 2016Research and Development Incyte, Jakafi, Jakavi, Novartis, Pancreatic cancer, colorectal cancer
Incyte said today that it is terminating its JANUS clinical trial programme testing blood cancer drug Jakafi in solid tumours …
Novartis blood cancer drug given EU nod
March 17, 2015Sales and Marketing Cancer, EU, Jakavi, Novartis, oncology, polycythemia vera, ruxolitinib
Novartis’ blood cancer drug Jakavi has been given the green light in Europe to treat adult patients with polycythemia vera …
Novartis earns EMA and FDA nods for Jakavi and Bexsero
January 26, 2015Sales and Marketing Bexsero, Cancer, EU, FDA, Jakavi, Novartis, US, meningitis, ruxolitinib
Novartis has secured the regulatory go-ahead for two of its drugs, after the EMA recommended Jakavi for a rare blood …
NICE rejects Jakavi
February 13, 2013Sales and Marketing Jakavi, NICE
NICE has today issued draft guidance saying it does not recommend Novartis’ Jakavi for patients with myelofibrosis, a rare blood …
Novartis’ 2012 results flat
January 24, 2013Sales and Marketing Bexsero, Jakavi, Novartis, generics, results
Generic competition has put a dent in Novartis’ financial results for 2012, with net sales down 3% year on year …
Novartis blood cancer hope
December 12, 2012Research and Development, Sales and Marketing Jakavi, Novartis, oncology
Two-year data from Novartis’s drug Jakavi suggests that it may improve overall survival in a rare form of cancer versus …
Novartis’ myelofibrosis treatment approved in Europe
August 28, 2012Sales and Marketing Incyte, Jakavi, Novartis, Orphan Drugs, myelofibrosis
Novartis’ Jakavi, a new treatment for patients with myelofibrosis has been approved in Europe. The drug was co-developed with Incyte, …
